BioCentury | Aug 4, 2008
Clinical News

INP 341 regulatory update

...III secretion system, flagellar motility and biofilm formation in certain Gram-negative bacteria, including Pseudomonas aeruginosa. Innate Pharmaceuticals AB...
BioCentury | Oct 23, 2006
Company News

Biocon, Innate Pharmaceuticals deal

...Phase II trial by late 2009 or early 2010. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Innate Pharmaceuticals AB...
BioCentury | Sep 29, 2003
Company News

Innate Pharmaceuticals, Siga deal

...III secretion system in Gram negative bacteria, with SIGA's bacterial genomics and small molecule development. Innate Pharmaceuticals AB...
Items per page:
1 - 3 of 3
BioCentury | Aug 4, 2008
Clinical News

INP 341 regulatory update

...III secretion system, flagellar motility and biofilm formation in certain Gram-negative bacteria, including Pseudomonas aeruginosa. Innate Pharmaceuticals AB...
BioCentury | Oct 23, 2006
Company News

Biocon, Innate Pharmaceuticals deal

...Phase II trial by late 2009 or early 2010. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Innate Pharmaceuticals AB...
BioCentury | Sep 29, 2003
Company News

Innate Pharmaceuticals, Siga deal

...III secretion system in Gram negative bacteria, with SIGA's bacterial genomics and small molecule development. Innate Pharmaceuticals AB...
Items per page:
1 - 3 of 3